Outcome of pediatric oncology patients with febrile neutropenia after introduction of a standard operating procedure for time-to-antibiotic therapy in a children's cancer center

Outcome of pediatric oncology patients with febrile neutropenia after introduction of a standard operating procedure for time-to-antibiotic therapy in a children's cancer center - TTA in FN

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029542

Enrollment

150

Registered

2022-07-06

Start date

2022-04-08

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fever in neutropenia D70

Interventions

Group 1: Data Collection All study related subject data will be captured in a pseudonymized form by a unique patient identification code. Following data are collected at least for each episode of FN

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: Pediatric oncology patients treated by home or external clinic/physician without prior treatment with fever in neutropenia (ANC <500) and/or in reduced general condition and/or with clinical signs of SIRS after chemotherapy in the pediatric emergency department or in the Oncology Outpatient Clinic of the Center for Pediatric and Adolescent Medicine from May 2019 to May 2021 and then admitted as inpatients Consent for inclusion in the Hilda Biobank with use of linked clinical data.

Exclusion criteria

Exclusion criteria: Patients with prior antibiotic treatment, fever without neutropenia or without change in general condition or signs of SIRS. Lack of consent for inclusion in the Hilda Biobank.

Design outcomes

Primary

Measure	Time frame
To determine the effect of an introduction of a standard operating procedure (SOP) for the treatment of FN on the TTA at the University Childrens Hospital of Freiburg. To assess the impact of the implemented SOP on the clinical course of FN in paediatric cancer patients presenting with FN.	—

Countries

Germany

Contacts

Public ContactAlexander Puzik

Kinder- und Jugendklinik des Universitätsklinikums Freiburg, Klinik für pädiatrische Hämatologie und Onkologie

alexander.puzik@uniklinik-freiburg.de+49-(0)761-270-43000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026